TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA® (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle.

纽约州塔里敦，2024年4月29日（环球通讯社）--Regeneron Pharmaceuticals，Inc.（纳斯达克：REGN）今天宣布，EYLEA®HD（aflibercept）注射液8 mg关键临床项目的长期阳性结果和亚组分析报告。这些报告是EYLEA HD和EYLEA®（aflibercept）注射液2 mg的14篇公认摘要的一部分，将于5月5日至9日在西雅图举行的视觉与眼科研究协会（ARVO）年会上分享。

“Our extensive data presentations at ARVO showcase the differentiated efficacy, safety and durability of EYLEA HD, and demonstrate our commitment to advancing retinal care for patients who are at risk of losing vision,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron.

Regeneron内科临床开发高级副总裁Boaz Hirshberg医学博士说：“我们在ARVO的广泛数据展示展示了EYLEA HD的不同疗效、安全性和耐久性，并证明了我们致力于为有视力丧失风险的患者推进视网膜护理。”。

“Since its FDA approval, we have seen growing use and positive patient and physician experiences with EYLEA HD in both treatment-experienced and treatment-naïve patients. The ARVO presentations highlight the encouraging real-world impact of EYLEA HD seen so far and reinforce its potential as a new standard-of-care for people living with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.” Notable podium presentations at ARVO include: One-year (48 week) data from the PHOTON trial investigating EYLEA HD in diabetic macular edema (DME) patients with or without prior treatment, compared to EYLEA.Two-year (96 week) results from the PULSAR trial investigating EYLEA HD in patients with wet age-related macular degeneration (wAMD), compared to EYLEA, which will feature a post-hoc analysis on the correlation of key baseline disease characteristics in wAMD to dosing intervals of EYLEA HD.A PULSAR subgroup analysis evaluating visual and anato.

“自FDA批准以来，我们看到EYLEA HD在有治疗经验和未接受治疗的患者中的使用越来越多，患者和医生的积极经验也越来越多。ARVO的介绍突出了迄今为止EYLEA HD令人鼓舞的现实世界影响，并加强了其作为湿性年龄相关性黄斑变性，糖尿病性黄斑水肿和糖尿病视网膜病变患者的新护理标准的潜力。”ARVO的重要讲台介绍包括：光子试验的一年（48周）数据，该试验调查了EYLEA HD在糖尿病性黄斑水肿（DME）患者中的治疗情况，与EYLEA相比。PULSAR试验研究了湿性年龄相关性黄斑变性（wAMD）患者的EYLEA HD的两年（96周）结果，与EYLEA相比，EYLEA将对wAMD中关键基线疾病特征与EYLEA HD给药间隔的相关性进行事后分析。脉冲星亚组分析评估视觉和解剖。